MacroGenics

MacroGenics

Yahoo Finance • 11 days ago

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Gilead Sciences (NASDAQ: GILD) has shifted from a period of stagnant growth, driven by slowing hepatitis C revenues and declining sales of its COVID-19 therapy Veklury, to a turnaround led by new HIV and oncology drugs. The pharmaceutical... Full story

Yahoo Finance • 14 days ago

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision trigge... Full story

Yahoo Finance • 15 days ago

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $... Full story

Yahoo Finance • 2 months ago

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy

Sanofi SA (NASDAQ:SNY) is one of the best dividend stocks yielding at least 5% to buy according to hedge funds. On June 22, Sanofi SA (NASDAQ:SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President and... Full story

Yahoo Finance • 4 months ago

Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Shares of Harmonic Inc(NASDAQ:HLIT) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Also, the company raised its FY26 EP... Full story

Yahoo Finance • 4 months ago

MacroGenics Secures $122.5M In Manufacturing Sale To Bora; Stock Up

(RTTNews) - MacroGenics, Inc. (MGNX) has entered into a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd (6472.TW), with Bora paying $122.5 million upfront upon closing. The dea... Full story

Yahoo Finance • 4 months ago

MacroGenics to sell manufacturing operations to Bora for $122.5M

* MacroGenics (MGNX [https://seekingalpha.com/symbol/MGNX]) said [https://seekingalpha.com/pr/20510112-macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals] on Monday it agreed to sell its GMP drug substance manufactu... Full story

Yahoo Finance • 4 months ago

B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. MacroGenics, Inc. is one of the best biotech stocks. TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 pri... Full story

Yahoo Finance • 5 months ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 5 months ago

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Neuroblastoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The neuroblastoma market has witnessed significant growth, projected to expand from $3.14 billion... Full story

Yahoo Finance • 6 months ago

Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) and MacroG... Full story

Yahoo Finance • 6 months ago

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s m... Full story

Yahoo Finance • 6 months ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that... Full story

Yahoo Finance • 10 months ago

After-Hours Gainers: MGNX, SLS, KRMD, HYPR, WVE Post Sharp Moves Following Q3 Updates

(RTTNews) - Several small-cap healthcare and biotech names posted notable price increases in after-hours trading on Wednesday, following earnings updates or ahead of scheduled financial disclosures. MacroGenics, Inc. (MGNX) rose 10.2% to... Full story

Yahoo Finance • 10 months ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending devel... Full story

Yahoo Finance • 10 months ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, Pr... Full story

Yahoo Finance • 10 months ago

3 Promising Penny Stocks With Market Caps Over $100M

Major stock indexes in the United States recently ended a mixed session, with the Dow Jones Industrial Average closing at a record high amid a flurry of corporate earnings reports. For investors seeking opportunities beyond the blue-chip s... Full story

Yahoo Finance • 11 months ago

What's going on in today's after hours session

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT SPRC [https://www.chartmill.co... Full story

Yahoo Finance • 12 months ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ P... Full story

Yahoo Finance • last year

Thursday's after hours session: top gainers and losers

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] GAINERS TICKER CHANGE COMMENT MODV [https://www.chartmill.com/stock/quote/MODV/... Full story